Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Feature Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationBG ControlType 2 DiabetesSpecial Edition - Postgraduate Medicine

How to Obtain Appropriate Type 2 Diabetes Control in the First 180 Days of Treatment Initiation

Louis Kuritzky, MD; Benjamin J. Epstein, PharmD, BCPS; and Frank Lavernia, MD

Abstract: Good control of diabetes provides meaningful microvascular risk reduction; yet, patients with type 2 diabetes mellitus commonly languish at unsatisfactory levels of glycated hemoglobin (HbA1c) for protracted periods. A variety of factors contribute to this clinical inertia, as clinicians tend to be too conservative in their treatment of patients who are not achieving glycemic control.

Advertisement

Available clinical data suggest the near-maximal blood glucose reduction achievable with use of most antidiabetic agents typically occurs within several weeks of treatment initiation. Based on this time course of action, we propose that optimal glycemic control can be attained within 180 days of treatment initiation by advancing antihyperglycemic therapy more rapidly than typical current practice. Our approach builds on current recommendations, though it seeks to redefine standard management of type 2 diabetes by placing greater emphasis on the timing of treatment intensification. We recommend the total period patients spend with uncontrolled hyperglycemia be minimized by shortening the number of steps along the treatment intensification ladder. This can be achieved by establishing combination therapy early in cases where baseline HbA1c levels are markedly elevated, including the prompt addition of basal insulin therapy when it becomes apparent that oral agents alone are unlikely to attain glycemic goals.

Conclusion

In light of the many possible treatment paths available for patients with type 2 diabetes, and the newer agents continually being developed, simple straightforward algorithms cannot replace the need for individualized management and clinical judgment. However, what we propose are some general principles for advancing therapy more rapidly to ensure more patients with type 2 diabetes reach recommended glycemic targets in a more timely fashion than is typical in today’s routine clinical practice. We suggest that, with the use of time course-directed therapy, most patients with type 2 diabetes should be able to attain reasonable glycemic control within the first 180 days of starting clinical care. Our approach builds on currently accepted recommendations but seeks to redefine standard management of type 2 diabetes by placing greater emphasis on the timing of treatment intensification. The total time patients spend with uncontrolled hyperglycemia should be reduced by initiating combination therapy, advancing the dosages of existing agents more aggressively, and quickly adding insulin therapy.

Regardless of the therapeutic agent chosen, more timely and aggressive intervention by health care providers can significantly improve glycemic control and long-term outcomes for many patients with type 2 diabetes. This can translate into reduced risk of kidney, nerve, and eyesight dysfunction, as well as cardiovascular diseases.

Click here for other articles at Postgraduate Medicine.

 

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 September, 2010 and appeared in  MedicationBG ControlType 2 DiabetesSpecial Edition - Postgraduate Medicine

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Second Tuberculosis Vaccine Treatment for Type 1 Diabetes Underway
Posted June 19, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?